Welcome to our dedicated page for Reshape Lifesciences SEC filings (Ticker: RSLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The journey from LAP-BAND® sales to the upcoming Diabetes Bloc-Stim neuromodulation trials means Reshape Lifesciences crams FDA milestones, clinical data, and cash-burn details into every SEC document. Finding the revenue split between the adjustable gastric band and Obalon Balloon, or pinpointing when RSLS last updated its expected regulatory timeline, can take hours.
Stock Titan’s AI reads each new Reshape Lifesciences quarterly earnings report 10-Q filing the moment it lands on EDGAR, extracts segment revenue, and flags liquidity warnings in plain English. Need Reshape Lifesciences insider trading Form 4 transactions? We stream Reshape Lifesciences Form 4 insider transactions real-time so you can spot executive stock moves before the market reacts. Our summaries turn a 300-page Reshape Lifesciences annual report 10-K simplified into concise bullet points, and every Reshape Lifesciences 8-K material events explained section highlights trial results or device recalls in seconds.
Whether you’re computing dilution risk ahead of the next capital raise, comparing reimbursement assumptions, or reviewing the Reshape Lifesciences proxy statement executive compensation, our platform answers natural questions like “understanding Reshape Lifesciences SEC documents with AI� and “Reshape Lifesciences earnings report filing analysis.� Stop sifting through exhibits; monitor pipeline progress, R&D spend, and Reshape Lifesciences executive stock transactions Form 4 in one place—with real-time alerts and expert context that help you act with confidence.
ReShape Lifesciences (RSLS) is asking its shareholders to approve two transformative transactions: (i) a reverse-merger with privately held Vyome Therapeutics and (ii) the sale of substantially all ReShape operating assets to U.K.-based Biorad for $2.25 million cash plus working-capital adjustments. At closing, Merger Sub will combine with Vyome, Vyome will survive as a wholly-owned subsidiary, and the parent will be renamed Vyome Holdings, Inc. The exchange ratio will be set 10 days before the special meeting so that Vyome security-holders own 88.9-92.31% of the fully-diluted shares, leaving current ReShape holders with 7.69-11.1%, subject to a net-cash true-up against a $5 million target.
ReShape’s balance-sheet assets (other than cash) and virtually all liabilities will transfer to Biorad, simplifying the combined company’s capital structure and sharpening its focus on Vyome’s immuno-inflammatory pipeline. ReShape has already loaned Vyome $400,000 at 8% interest to cover merger expenses; the note will be forgiven at closing but becomes senior secured if the deal fails due to financing issues. To retain a Nasdaq listing, the combined company must satisfy initial listing standards, including a $4.00 minimum share price; if approved, the ticker is expected to change to “H±ő±·¶Ů.â€�
ReShape will hold a virtual special meeting where shareholders will vote on (1) issuing new shares for the merger and (2) approving the asset sale. Vyome has already secured written consent from >50% of its voting shares, so no Vyome meeting is required. The boards of both companies unanimously recommend voting “FOR� all proposals, but completion remains contingent on shareholder approval and Nasdaq acceptance.
ReShape Lifesciences (Nasdaq: RSLS) filed an 8-K (Item 8.01 � Other Events) disclosing its current status with Nasdaq listing requirements. On May 28 2025 the company received a delisting notice for failing to meet the Nasdaq Capital Market’s minimum $2.5 million stockholders� equity requirement; equity stood at only $1.2 million as of March 31 2025.
Since the notice, ReShape raised additional capital in two transactions: (1) 593,000 common shares sold between June 3�6 2025 via its at-the-market program for $3.64 million gross proceeds, and (2) an offering completed June 9 2025 of 1,054,604 shares for $2.64 million gross proceeds. Pro forma for these raises, management states that stockholders� equity now exceeds $2.5 million.
The company has requested a hearing before a Nasdaq Hearings Panel, which automatically stays any suspension or delisting action until the Panel issues a decision and any permitted extension period expires. Management cautions that merely surpassing the equity threshold does not guarantee continued listing; the final outcome depends on the Panel’s review.
Investors should monitor the Panel’s ruling and ReShape’s ability to sustain equity levels, as delisting would shift trading to an over-the-counter venue and could impact liquidity and valuation.
FAQ
What is the current stock price of Reshape Lifesciences (RSLS)?
What is the market cap of Reshape Lifesciences (RSLS)?
What is the primary focus of Reshape Lifesciences Inc.?
How does the company address obesity treatment?
What types of products does Reshape Lifesciences include in its portfolio?
How does the company integrate digital health into its product offerings?
What sets Reshape Lifesciences apart from traditional surgical solutions?
In which market segments does Reshape Lifesciences operate?
What are the key benefits of the company’s product approaches?
How is Reshape Lifesciences positioned within the competitive landscape?
